DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,633,113 | +28.1% | 55,341 | 0.0% | 0.06% | +29.5% |
| Q1 2023 | $1,275,057 | -17.2% | 55,341 | 0.0% | 0.04% | -25.4% |
| Q4 2022 | $1,539,033 | -1.6% | 55,341 | +8.6% | 0.06% | -9.2% |
| Q3 2022 | $1,564,000 | +4.3% | 50,971 | 0.0% | 0.06% | +14.0% |
| Q2 2022 | $1,500,000 | -8.5% | 50,971 | 0.0% | 0.06% | +14.0% |
| Q1 2022 | $1,640,000 | -27.8% | 50,971 | 0.0% | 0.05% | -20.6% |
| Q4 2021 | $2,273,000 | +46.4% | 50,971 | +65.5% | 0.06% | +43.2% |
| Q3 2021 | $1,553,000 | -35.7% | 30,791 | 0.0% | 0.04% | -21.4% |
| Q2 2021 | $2,415,000 | +37.4% | 30,791 | 0.0% | 0.06% | +43.6% |
| Q1 2021 | $1,758,000 | -31.8% | 30,791 | 0.0% | 0.04% | -33.9% |
| Q4 2020 | $2,579,000 | +1.7% | 30,791 | -56.5% | 0.06% | -6.3% |
| Q3 2020 | $2,537,000 | +48.2% | 70,793 | 0.0% | 0.06% | +61.5% |
| Q2 2020 | $1,712,000 | +38.1% | 70,793 | 0.0% | 0.04% | +25.8% |
| Q1 2020 | $1,240,000 | – | 70,793 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |